FDA Advisors Vote to Recommend Moderna Boosters

France Nouvelles Nouvelles

FDA Advisors Vote to Recommend Moderna Boosters
France Dernières Nouvelles,France Actualités
  • 📰 WebMD
  • ⏱ Reading Time:
  • 50 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 23%
  • Publisher: 51%

A panel of experts that advises the FDA on vaccine decisions voted unanimously Thursday to approve booster doses of Moderna’s COVID-19 vaccine.

/webmd/consumer_assets/site_images/article_thumbnails/video/covid19-images/Topol_092821_1800x1200b.jpg“The data are not perfect, but these are extraordinary times and we have to work with data that are not perfect,” said Eric Rubin, MD, editor-in-chief ofPatrick Moore, MD, a professor at the University of Pittsburgh Cancer Institute who is also a temporary voting member, said he voted to approve the Moderna boosters based “more on a gut feeling than on truly serious data.

Next, the FDA will have to formally sign off on the emergency use authorization, which it is expected to do. Then, the CDC’s Advisory Committee on Immunization Practices will meet to make formal recommendations on use of the Moderna boosters. That group is scheduled to meet next Thursday to take up questions of exactly how these boosters should be used.

Peter Marks, MD, head of the FDA’s Center for Biologics Evaluation and Research, cautioned that the CDC is more constrained in making recommendations under an emergency use authorization than it would be if the boosters had gotten full approval. So it will likely align its vote with the conditions of the emergency use authorization from the FDA.Overall, data shows that two doses of the Modernaremains highly effective at preventing hospitalization and death.

Data presented by Moderna today showed the risk of breakthrough infections increased by 36% in study participants who received the vaccine in their

Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite:

WebMD /  🏆 709. in US

France Dernières Nouvelles, France Actualités

Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.

FDA panel debates lower-dose Moderna COVID shots for boosterFDA panel debates lower-dose Moderna COVID shots for boosterU.S. health advisers are debating if millions of Americans who received Moderna vaccinations should get a booster shot -- this time, using half the original dose. Already millions who got their initial Pfizer shots at least six months ago are getting a booster of that brand.
Lire la suite »

Independent FDA panel votes to authorize Moderna booster for seniors and high-risk AmericansIndependent FDA panel votes to authorize Moderna booster for seniors and high-risk AmericansBREAKING: An independent FDA advisory panel voted unanimously to authorize Moderna Covid-19 vaccine boosters for Americans 65 and older, anyone 18 and older with underlying conditions and those frequently exposed to the virus.
Lire la suite »

FDA panel endorses lower-dose Moderna COVID shot for boosterFDA panel endorses lower-dose Moderna COVID shot for boosterU.S. health advisers said Thursday that some Americans who received Moderna’s COVID-19 vaccine should get a half-dose booster to bolster protection against the virus. The panel of advisers to the Food and Drug Administration voted unanimously to recommend a booster shot for seniors, adults with other health problems, jobs or living situations that put them at increased risk for COVID-19.
Lire la suite »

FDA panel unanimously endorses Moderna boosters for certain populationsFDA panel unanimously endorses Moderna boosters for certain populationsMembers of the Food and Drug Administration’s vaccine expert panel on Thursday endorsed boosters for Moderna recipients who are at high risk of severe COVID-19, occupational exposure to COVID-19 or are 65 years and older.Why it matters: The unanimous decision mirrors the FDA conditions for those who qualify for a Pfizer booster.Stay on top of the latest market trends and economic insights with Axios Markets. Subscribe for freeBe smart: Despite small data sample sizes and limited data, the agency
Lire la suite »

FDA Staff Don’t Take Position on Moderna Covid-19 BoosterFDA Staff Don’t Take Position on Moderna Covid-19 BoosterIn an unusual move, FDA staff didn't take a position on Moderna's application for a booster shot, indicating there may be insufficient data to support one
Lire la suite »



Render Time: 2025-04-17 12:12:03